{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "25877744", "DateCompleted": {"Year": "2016", "Month": "02", "Day": "23"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "21"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2015", "Month": "04", "Day": "17"}], "ELocationID": ["10.1007/s00213-015-3928-8"], "Journal": {"ISSN": "1432-2072", "JournalIssue": {"Volume": "232", "Issue": "16", "PubDate": {"Year": "2015", "Month": "Aug"}}, "Title": "Psychopharmacology", "ISOAbbreviation": "Psychopharmacology (Berl)"}, "ArticleTitle": "Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.", "Pagination": {"StartPage": "2921", "EndPage": "2938", "MedlinePgn": "2921-38"}, "Abstract": {"AbstractText": ["Major depression has been associated with higher levels of air pollution that in turn leads to neurodegeneration via increased oxidative stress. There is a need for suitable translational animal models to study the role of oxidative stress in depression and antidepressant action.", "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat. In addition, response to the antioxidant melatonin, and the antidepressants desipramine or escitalopram, was assessed.", "Rats were exposed to ozone (0.0 or 0.3 parts per million (ppm)) per inhalation for 4 h daily for a period of 15 days, while simultaneously receiving saline or the above-mentioned drugs.", "The data indicate that chronic ozone inhalation induced memory impairment, anxiety and depression-like effects, reduced cortical and hippocampal superoxide dismutase and catalase activity, and compromised central monoamine levels similar to that noted in depression. Moreover, the behavioral and neurochemical effects of melatonin, desipramine, and escitalopram were mostly attenuated in the presence of ozone.", "Thus, genetically susceptible individuals exposed to high levels of oxidative stress are at higher risk of developing mood and/or an anxiety disorders, showing greater redox imbalance and altered behavior. These animals are also more resistant to contemporary antidepressant treatment. The presented model provides robust face, construct, and predictive validity, suitable for studying neuronal oxidative stress in depression, antidepressant action and mechanisms to prevent neuronal oxidative stress."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology, School of Pharmacy, North-West University, Potchefstroom, 2520, South Africa."}], "LastName": "Mokoena", "ForeName": "Mmalebuso L", "Initials": "ML"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Harvey", "ForeName": "Brian H", "Initials": "BH"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Viljoen", "ForeName": "Francois", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Ellis", "ForeName": "Susanna M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Brink", "ForeName": "Christiaan B", "Initials": "CB"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Psychopharmacology (Berl)", "NlmUniqueID": "7608025", "ISSNLinking": "0033-3158"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents"}, {"RegistryNumber": "0DHU5B8D6V", "NameOfSubstance": "Citalopram"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "JL5DK93RCL", "NameOfSubstance": "Melatonin"}, {"RegistryNumber": "TG537D343B", "NameOfSubstance": "Desipramine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antidepressive Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Behavior, Animal"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Citalopram"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Depression"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Depressive Disorder, Major"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Desipramine"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Hippocampus"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Melatonin"}, {"QualifierName": ["drug effects"], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Rats"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Environ Health Perspect. 2011 May;119(5):682-7", "ArticleIdList": ["21172758"]}, {"Citation": "Ann N Y Acad Sci. 2001 Apr;928:168-75", "ArticleIdList": ["11795507"]}, {"Citation": "Ann N Y Acad Sci. 1994 May 31;719:1-12", "ArticleIdList": ["8010585"]}, {"Citation": "Arch Environ Health. 1972 Mar;24(3):153-9", "ArticleIdList": ["4258218"]}, {"Citation": "Biol Psychiatry. 2003 Nov 15;54(10):1105-17", "ArticleIdList": ["14625154"]}, {"Citation": "Physiol Behav. 2006 Jan 30;87(1):95-102", "ArticleIdList": ["16197969"]}, {"Citation": "Neurochem Res. 2008 Mar;33(3):508-17", "ArticleIdList": ["17763945"]}, {"Citation": "Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):331-8", "ArticleIdList": ["7667349"]}, {"Citation": "Cell Mol Neurobiol. 2013 Aug;33(6):825-35", "ArticleIdList": ["23801192"]}, {"Citation": "Toxicol Lett. 2010 Sep 1;197(3):193-200", "ArticleIdList": ["20541596"]}, {"Citation": "Neurosci Biobehav Rev. 2009 May;33(5):699-771", "ArticleIdList": ["19428491"]}, {"Citation": "Metab Brain Dis. 2013 Dec;28(4):687-96", "ArticleIdList": ["24000072"]}, {"Citation": "Physiol Behav. 2006 May 30;87(5):881-90", "ArticleIdList": ["16546226"]}, {"Citation": "Physiol Behav. 2001 Aug;73(5):705-17", "ArticleIdList": ["11566205"]}, {"Citation": "Pharmacol Biochem Behav. 2011 Jun;98(4):511-7", "ArticleIdList": ["21352847"]}, {"Citation": "J Clin Psychiatry. 2014 Jun;75(6):628-36", "ArticleIdList": ["25004186"]}, {"Citation": "Metab Brain Dis. 2010 Jun;25(2):125-33", "ArticleIdList": ["20455016"]}, {"Citation": "Neurosci Biobehav Rev. 2005;29(4-5):739-59", "ArticleIdList": ["15925699"]}, {"Citation": "Eur J Pharmacol. 2004 May 25;492(2-3):195-201", "ArticleIdList": ["15178365"]}, {"Citation": "Neurochem Int. 2004 Dec;45(7):979-86", "ArticleIdList": ["15337296"]}, {"Citation": "Psychoneuroendocrinology. 2013 Aug;38(8):1349-61", "ArticleIdList": ["23267723"]}, {"Citation": "Brain Res. 2003 Jan 3;959(1):128-34", "ArticleIdList": ["12480166"]}, {"Citation": "Eur J Pharmacol. 2012 Nov 15;695(1-3):71-5", "ArticleIdList": ["22981666"]}, {"Citation": "Neurosci Biobehav Rev. 2013 Sep;37(8):1380-402", "ArticleIdList": ["23680698"]}, {"Citation": "Psychopharmacology (Berl). 2006 Jan;183(4):404-12", "ArticleIdList": ["16307295"]}, {"Citation": "Fundam Clin Pharmacol. 2009 Feb;23(1):89-95", "ArticleIdList": ["19207541"]}, {"Citation": "Toxicol Sci. 2010 Jan;113(1):187-97", "ArticleIdList": ["19833740"]}, {"Citation": "Pharmacol Rev. 2013 Jan 10;65(1):143-55", "ArticleIdList": ["23319547"]}, {"Citation": "Neurosci Lett. 2008 Aug 22;441(2):178-82", "ArticleIdList": ["18577417"]}, {"Citation": "Am J Psychiatry. 1976 Oct;133(10):1181-6", "ArticleIdList": ["788529"]}, {"Citation": "J Comp Physiol Psychol. 1955 Aug;48(4):254-60", "ArticleIdList": ["13252152"]}, {"Citation": "Brain Behav Immun. 2013 May;30:156-67", "ArticleIdList": ["23270677"]}, {"Citation": "Neurosci Lett. 1999 Jul 30;270(2):107-9", "ArticleIdList": ["10462109"]}, {"Citation": "Physiol Behav. 2013 Jul 2;119:201-7", "ArticleIdList": ["23810991"]}, {"Citation": "Pflugers Arch. 1997 Apr;433(6):744-9", "ArticleIdList": ["9049165"]}, {"Citation": "Hum Psychopharmacol. 2007 Mar;22(2):67-73", "ArticleIdList": ["17299810"]}, {"Citation": "J Chem Neuroanat. 2006 Feb;31(2):114-23", "ArticleIdList": ["16236481"]}, {"Citation": "Nat Rev Drug Discov. 2005 Sep;4(9):775-90", "ArticleIdList": ["16138108"]}, {"Citation": "Mitochondrion. 2008 Jun;8(3):273-8", "ArticleIdList": ["18558519"]}, {"Citation": "J Affect Disord. 1995 Oct 9;35(1-2):1-9", "ArticleIdList": ["8557882"]}, {"Citation": "Neurosci Lett. 2003 May 29;343(1):1-4", "ArticleIdList": ["12749983"]}, {"Citation": "Cell Biochem Biophys. 2001;34(2):237-56", "ArticleIdList": ["11898866"]}, {"Citation": "Neuropsychobiology. 2013;67(1):33-40", "ArticleIdList": ["23221974"]}, {"Citation": "Behav Pharmacol. 2009 May;20(3):273-85", "ArticleIdList": ["19424057"]}, {"Citation": "J Neurosci Res. 2006 Nov 1;84(6):1292-302", "ArticleIdList": ["17099915"]}, {"Citation": "J Biomed Sci. 2000 Nov-Dec;7(6):444-58", "ArticleIdList": ["11060493"]}, {"Citation": "Arch Gen Psychiatry. 1986 Sep;43(9):870-5", "ArticleIdList": ["3753164"]}, {"Citation": "J Psychopharmacol. 2011 Oct;25(10):1378-87", "ArticleIdList": ["21262856"]}, {"Citation": "Biol Signals Recept. 2000 May-Aug;9(3-4):160-71", "ArticleIdList": ["10899701"]}, {"Citation": "Physiol Res. 2005;54(3):341-8", "ArticleIdList": ["15588163"]}, {"Citation": "J Affect Disord. 2001 Apr;64(1):43-51", "ArticleIdList": ["11292519"]}, {"Citation": "Eur Neuropsychopharmacol. 2011 Jun;21(6):471-83", "ArticleIdList": ["20965701"]}, {"Citation": "Exp Physiol. 1997 Mar;82(2):291-5", "ArticleIdList": ["9129943"]}, {"Citation": "Mol Psychiatry. 2011 Oct;16(10):987-95, 973", "ArticleIdList": ["21727897"]}, {"Citation": "Eur Psychiatry. 2002 Jul;17 Suppl 3:306-10", "ArticleIdList": ["15177086"]}, {"Citation": "Free Radic Biol Med. 1995 Dec;19(6):903-9", "ArticleIdList": ["8582667"]}, {"Citation": "Behav Brain Res. 2012 Mar 1;228(1):16-21", "ArticleIdList": ["22173002"]}, {"Citation": "Brain Res Bull. 2002 Aug 15;58(4):345-50", "ArticleIdList": ["12183009"]}, {"Citation": "Behav Brain Res. 2012 Apr 21;230(1):85-91", "ArticleIdList": ["22321459"]}, {"Citation": "Neuro Endocrinol Lett. 2009;30(4):462-9", "ArticleIdList": ["20010493"]}, {"Citation": "Neuropsychopharmacology. 2003 Apr;28(4):694-703", "ArticleIdList": ["12655314"]}, {"Citation": "Neuroscience. 1999 Jan;88(2):609-15", "ArticleIdList": ["10197779"]}, {"Citation": "Eur J Pharmacol. 2003 Feb 28;463(1-3):35-53", "ArticleIdList": ["12600701"]}, {"Citation": "Pharmacol Biochem Behav. 2003 Mar;74(4):891-900", "ArticleIdList": ["12667904"]}, {"Citation": "Biochem Biophys Res Commun. 1998 Oct 9;251(1):83-7", "ArticleIdList": ["9790911"]}, {"Citation": "Int J Neurosci. 2001;108(3-4):193-200", "ArticleIdList": ["11699191"]}, {"Citation": "Cell Tissue Res. 2002 Jul;309(1):151-62", "ArticleIdList": ["12111545"]}, {"Citation": "Cell Mol Life Sci. 2004 Jan;61(2):192-208", "ArticleIdList": ["14745498"]}, {"Citation": "Int J Dev Neurosci. 2011 Jun;29(4):365-75", "ArticleIdList": ["21458557"]}, {"Citation": "Neurosci Biobehav Rev. 2012 Feb;36(2):764-85", "ArticleIdList": ["22197082"]}, {"Citation": "Biomed Pharmacother. 2005 May;59(4):139-42", "ArticleIdList": ["15862706"]}, {"Citation": "J Affect Disord. 1992 May;25(1):77-86", "ArticleIdList": ["1624647"]}, {"Citation": "Neuropeptides. 2011 Dec;45(6):401-6", "ArticleIdList": ["21871662"]}, {"Citation": "Neurosci Lett. 2005 Sep 16;385(3):234-9", "ArticleIdList": ["15970378"]}, {"Citation": "Synapse. 2013 Mar;67(3):127-34", "ArticleIdList": ["23152197"]}, {"Citation": "Acta Biochim Pol. 2007;54(1):1-9", "ArticleIdList": ["17351668"]}, {"Citation": "Anal Biochem. 1976 May 7;72:248-54", "ArticleIdList": ["942051"]}, {"Citation": "Ann N Y Acad Sci. 2001 Jun;939:200-15", "ArticleIdList": ["11462772"]}, {"Citation": "Mutat Res. 1999 Mar 8;424(1-2):51-8", "ArticleIdList": ["10064849"]}, {"Citation": "Exp Gerontol. 2012 Sep;47(9):706-11", "ArticleIdList": ["22796061"]}, {"Citation": "Behav Pharmacol. 2008 Oct;19(7):747-50", "ArticleIdList": ["18797252"]}, {"Citation": "J Pineal Res. 2011 Aug;51(1):1-16", "ArticleIdList": ["21752095"]}, {"Citation": "Exp Toxicol Pathol. 2013 Jul;65(5):503-11", "ArticleIdList": ["22436577"]}, {"Citation": "Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):325-31", "ArticleIdList": ["11701204"]}, {"Citation": "Neurotoxicology. 2012 Oct;33(5):972-84", "ArticleIdList": ["22981845"]}, {"Citation": "Biol Psychiatry. 1997 Jan 1;41(1):23-32", "ArticleIdList": ["8988792"]}, {"Citation": "Behav Pharmacol. 2006 Feb;17(1):9-18", "ArticleIdList": ["16377959"]}, {"Citation": "Int J Physiol Pathophysiol Pharmacol. 2009 Jun 20;1(2):154-161", "ArticleIdList": ["21383885"]}, {"Citation": "Biol Psychiatry. 2008 Sep 15;64(6):468-75", "ArticleIdList": ["18534556"]}, {"Citation": "Eur J Pharmacol. 2004 Aug 16;497(1):49-53", "ArticleIdList": ["15321734"]}, {"Citation": "Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):215-20", "ArticleIdList": ["23621786"]}, {"Citation": "Brain Res. 2010 Sep 24;1353:204-12", "ArticleIdList": ["20624374"]}, {"Citation": "Int J Neuropsychopharmacol. 2008 Sep;11(6):851-76", "ArticleIdList": ["18205981"]}, {"Citation": "Psychiatr Pol. 2007 Sep-Oct;41(5):615-24", "ArticleIdList": ["18421918"]}, {"Citation": "Neural Plast. 2013;2013:537265", "ArticleIdList": ["23862076"]}, {"Citation": "J Psychiatry Neurosci. 2004 May;29(3):174-84", "ArticleIdList": ["15173894"]}, {"Citation": "Eur J Pharmacol. 1993 Jun 24;237(2-3):231-6", "ArticleIdList": ["8103462"]}], "ReferenceList": []}], "History": [{"Year": "2014", "Month": "9", "Day": "17"}, {"Year": "2015", "Month": "3", "Day": "24"}, {"Year": "2015", "Month": "4", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "4", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "2", "Day": "26", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["25877744", "10.1007/s00213-015-3928-8"]}}], "PubmedBookArticle": []}